Skip to main content
  • MediGene and Will-Pharma Sign Agreement for the Commercialization of Veregen® in Benelux

    March 10, 2011

Martinsried/Munich, March 10, 2011. The biotech company MediGene AG (Frankfurt, Prime Standard) has signed an exclusive license and supply agreement with Will-Pharma for the commercialization and marketing of Veregen® ointment in Belgium, the Netherlands and Luxembourg. Will-Pharma will market, promote and distribute the drug for the treatment of genital warts. Further financial details of the agreement were not disclosed.

MediGene has already entered into several marketing partnerships for Veregen®, e.g. with Nycomed for the USA, with Abbott for Germany, Austria, and Switzerland, with Expanscience for France, with Juste for Spain and Portugal as well as with a number of other partners across Europe, Latin America and Asia. MediGene is planning to continue this global licensing strategy.

Veregen® is currently available on the US, German and Austrian markets. A second wave of marketing applications under the European mutual recognition procedure is planned, with Germany serving as the reference state in this process.